Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are up during Thursday’s premarket session as the company has entered into a settlement agreement with Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).
This news comes amidst a mixed market backdrop, with S&P 500 futures showing a slight loss of 0.03%.
Aurinia (AUPH) Settles Patent Litigation With Teva
Under the terms of the settlement, Teva has stipulated that Aurinia’s U.S. Patent Nos. 10,286,036 and 11,622,991 (which expire in December 2037) are enforceable, valid, and would be infringed by commercial sales within the U.S. of its generic voclosporin product.
The settlement further provides that Teva may launch its generic voclosporin product no earlier than Dec. 7, 2036, unless certain defined contingencies occur earlier.
